TTGM 5826, and other small molecules tested against tTG, were obtained from ChemBridge (San Diego, CA). GSCs were obtained as previously described [60 (link), 61 (link)]. All other cell lines used in the study were purchased from the ATCC (Manassas, VA). RPMI 1640, DMEM, DMEM-F12, Penicillin/Streptomycin, Fungizone, B27 supplement, heparin, bFGF, EGF, Trip-LE, trypsin-EDTA, bodipy-GTP-γS, horse serum (HS), and fetal bovine serum (FBS) were purchased from Invitrogen (Waltham, MA). MEGM was obtained from Lonza (Allendale, NJ). Recombinant tTG was prepared as previously described [51 (link)]. HRP-conjugated streptavidin and BPA were obtained from Pierce Biotechnology (Waltham, MA), and the human-specific tTG antibody (MS-300-P, used for human-derived cancer cells) was from Neomarkers (Fremont, CA). The mouse-specific TG antibody (A033, used for MEFs) and Z-Don were from Zedira GMBH (Darmstadt, Germany). The anti-rabbit IgG-HRP (7074S), anti-mouse IgG-HRP (7076S), and HA antibodies (3724S) were from Cell Signaling (Danvers, MA). The vinculin antibody (V9131), purified trypsin, soybean trypsin inhibitor, temozolomide, vincristine, carmustine, MDC, DMSO, and NNDC were obtained from Sigma Aldrich (St. Louis, MO).
Free full text: Click here